8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  June 10, 2008

EXPRESS SCRIPTS, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE	0-20199	43-1420563
(State or Other Jurisdiction of Incorporation or Organization	(Commission File Number)	(I.R.S. Employer Identification No.)

One Express Way, St. Louis, MO (Address of Principal Executive Offices) 63121 (Zip Code)

Registrant’s telephone number including area code: 314-996-0900

No change since last report

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On June 10, 2008, Express Scripts, Inc. announced that it had entered into an agreement to sell its infusion pharmacy business.   The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits

 (d)    The following Exhibits are furnished as part of this report on Form 8-K:

  Exhibit 99.1   Press Release, dated June 10, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	EXPRESS SCRIPTS, INC.
	(Registrant)
Date:  June 10, 2008	By:	/s/ Thomas M. Boudreau
		Thomas M. Boudreau
		Executive Vice President, Law & Strategy

EX-99.1

                                                                                                                                           ;                                                                                                                                                                          &# 160;                                                                                                                                                          [Missing

Contact:

Jeff Hall, Chief Financial Officer

David Myers, Vice President Investor Relations

(314)   810-3115

investor.relations@express-scripts.com                                                                                                                             ;    

Express Scripts Announces Sale of Infusion Pharmacy Business

ST. LOUIS, June 10, 2008—Express Scripts, Inc. (Nasdaq: ESRX) announced that is has signed a definitive agreement to sell its Infusion Pharmacy business to Option Care, Inc., a wholly-owned subsidiary of Walgreen Co. (NYSE: WAG) for an undisclosed amount.

“We previously announced that the infusion business was not a strategic fit with our core PBM and specialty pharmacy operations,” stated George Paz, president, chief executive officer and chairman.  “As a result, we are selling this business to Option Care, which is a leading home infusion company, with operational expertise in this marketplace.”

The Infusion Pharmacy business is classified as discontinued operations in Express Scripts’ financial statements.  The transaction is expected to close within approximately 30 days.

About Express Scripts

Express Scripts, Inc. is one of the largest PBM companies in North America, providing PBM services to thousands of client groups, including managed-care organizations, insurance carriers, employers, third-party administrators, public sector, workers compensation, and union-sponsored benefit plans.

Express Scripts provides integrated PBM services, including network-pharmacy claims processing, home delivery services, benefit-design consultation, drug-utilization review, formulary management, and medical- and drug-data analysis services.  The Company also distributes a full range of biopharmaceutical products directly to patients or their physicians, and provides extensive cost-management and patient-care services.

Express Scripts is headquartered in St. Louis, Missouri. More information can be found at http://www.express-scripts.com, which includes expanded investor information and resources.